Dual-energy X-ray aborptiometry assessment in children and adolescents with diseases that may affect the skeleton:: The 2007 ISCD Pediatric Official Positions

被引:86
作者
Bishop, Nick [1 ]
Braillon, Pierre [2 ]
Burnham, Jon [3 ]
Cimaz, Rolando [4 ]
Davies, Justin [5 ]
Fewtrell, Mary [6 ]
Hogler, Wolfgang [7 ]
Kennedy, Kathy [6 ]
Makitie, Outi [8 ]
Mughal, Zulf [9 ]
Shaw, Nick [10 ]
Vogiatzi, Maria [11 ]
Ward, Kate [12 ]
Bianchi, Maria Luisa [13 ]
机构
[1] Univ Sheffield, Sheffield Childrens NHS Fdn Trust, Sheffield S10 2TH, S Yorkshire, England
[2] Hosp Debrousse, Lyon, France
[3] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA
[4] Azienda Osped Univ Meyer, Florence, Italy
[5] Southampton Univ Hosp Trust, Southampton, Hants, England
[6] Childhood Nutr Res Ctr, Inst Child Hlth, London, England
[7] Prince Wales Childrens Hosp, Birmingham, W Midlands, England
[8] Helsinki Univ Hosp, Helsinki, Finland
[9] St Marys Hosp Women & Children, Manchester, Lancs, England
[10] Birmingham Childrens Hosp, Birmingham, W Midlands, England
[11] New York Presbyterian Hosp, New York, NY USA
[12] Univ Manchester, Manchester, Lancs, England
[13] IRCCS, Ist Auxol, Milan, Italy
关键词
body size; chronic disease; frequency; low bone mass; monitoring; osteoporosis;
D O I
10.1016/j.jocd.2007.12.004
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The Task Force focusing on the use of dual energy X-ray absorptiometry (DXA) in children and adolescents with diseases that may affect the skeleton reviewed over 300 articles to establish the basis for the Official Positions. A significant number of studies used DXA-based outcome measures to assess the effects of specific interventions and charted the natural history of incremental changes in bone size and mass in specific disease states in children. However, the utility of DXA in clinical practice has not been evaluated systematically, in large part due to the lack of a workable definition for childhood osteoporosis. Thus, in combination with the Official Positions addressing the diagnosis of osteoporosis in children, and the reporting of DXA results in children, this document presents clear guidelines from which clinicians and researchers alike can work. This report delineates a set of disorders in which it is appropriate to use DXA as part of the comprehensive assessment of skeletal health in children and adolescents, and provides guidance concerning the initiation of assessment and the frequency of monitoring. Importantly, this document also highlights significant gaps in our knowledge, emphasizing areas for future research.
引用
收藏
页码:29 / 42
页数:14
相关论文
共 210 条
[1]   Growth hormone therapy improves bone mineral density in children with cerebral palsy: A preliminary pilot study [J].
Ali, Omar ;
Shim, Melanie ;
Fowler, Eileen ;
Greenberg, Marcia ;
Perkins, Donna ;
Oppenheim, William ;
Cohen, Pinchas .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2007, 92 (03) :932-937
[2]   FRACTURES IN PREMATURE-INFANTS [J].
AMIR, J ;
KATZ, K ;
GRUNEBAUM, M ;
YOSIPOVICH, Z ;
WIELUNSKY, E ;
REISNER, SH .
JOURNAL OF PEDIATRIC ORTHOPAEDICS, 1988, 8 (01) :41-44
[3]   THE CONTRIBUTION OF HYPOGONADISM TO THE DEVELOPMENT OF OSTEOPOROSIS IN THALASSEMIA MAJOR - NEW THERAPEUTIC APPROACHES [J].
ANAPLIOTOU, MLG ;
KASTANIAS, IT ;
PSARA, P ;
EVANGELOU, EA ;
LIPARAKI, M ;
DIMITRIOU, P .
CLINICAL ENDOCRINOLOGY, 1995, 42 (03) :279-287
[4]  
Angastiniotis M, 1998, J PEDIATR ENDOCR MET, V11, P779
[5]   Reduced bone mineral density in long-term survivors of childhood acute lymphoblastic leukemia [J].
Arikoski, P ;
Komulainen, J ;
Voutilainen, R ;
Riikonen, P ;
Parviainen, M ;
Tapanainen, P ;
Knip, M ;
Kroger, H .
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 1998, 20 (03) :234-240
[6]   Intravenous pamidronate treatment in children with moderate to severe osteogenesis imperfecta: assessment of indices of dual-energy X-ray absorptiometry and bone metabolic markers during the first year of therapy [J].
Arikoski, P ;
Silverwood, B ;
Tillmann, V ;
Bishop, NJ .
BONE, 2004, 34 (03) :539-546
[7]  
Åström E, 1998, ACTA PAEDIATR, V87, P64
[8]   Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta [J].
Åström, E ;
Söderhäll, S .
ARCHIVES OF DISEASE IN CHILDHOOD, 2002, 86 (05) :356-364
[9]   Intravenous pamidronate treatment of infants with severe osteogenesis imperfecta [J].
Astrom, Eva ;
Jorulf, Hakan ;
Soderhall, Stefan .
ARCHIVES OF DISEASE IN CHILDHOOD, 2007, 92 (04) :332-338
[10]  
Atkinson SA, 1998, INT J CANCER, V78, P35